Lyell Immunopharma develops next-generation CAR T-cell therapies intended to produce durable remissions in patients with hematologic malignancies and solid tumors. The clinical-stage company applies proprietary technologies to engineer T cells with enhanced persistence, resistance to exhaustion, and stem-like qualities suited to the tumor microenvironment. It maintains integrated capabilities in discovery, manufacturing, and clinical development to advance its pipeline of cell therapy product candidates.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -42.7 | — |
| Q3 2025 | 0 | — | -38.9 | — |
| Q4 2025 | 0 | — | -140.7 | — |
| Q1 2026 | 0 | — | -24.1 | — |
| Q2 2026 | 0 | -50% | -44.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: TON Strategy Co (TONX), Invivyd, Inc. (IVVD), Neostellar Capital Corp. (NSLR), TROOPS, Inc. (TROO), Harvard Ave Acquisition Corporation (HAVA), Asure Software, Inc. (ASUR)